Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (NCT07355257) titled 'TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)' on Jan. 19.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Zhongming Qiu
Condition:
Inflammatory Myopathy
Intervention:
Drug: Telitacicept 240mg
Recruitment Status: Not recruiting
Phase: Phase 2/Phase 3
Date of First Enrollment: February 2, 2026
Target Sample Size: 30
To know more, visit https://clinicaltrials.gov/study/NCT07355257
Disclaimer: Curated by HT Syndication....